ReviewDrugs2008
Pharmacological management of epilepsy: recent advances and future prospects.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Brivaracetam add-on therapy for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2022Pooled it
- Brivaracetam add-on therapy for drug-resistant epilepsy.The Cochrane database of systematic reviews · 2019Pooled it
- Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.Neuroscience bulletin · 2024Review
- Exploring the pathogenesis of canine epilepsy using a systems genetics method and implications for anti-epilepsy drug discovery.Oncotarget · 2018Article
- Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: a network meta-analysis.Journal of neurology · 2018Review
- Emerging drugs for partial-onset epilepsy: a review of brivaracetam.Therapeutics and clinical risk management · 2016Article
- Prevalence of Different Combinations of Antiepileptic Drugs and CNS Drugs in Elderly Home Care Service and Nursing Home Patients in Norway.Epilepsy research and treatment · 2016Article
- Pediatric indications for deep brain stimulation.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Review
- Pharmacological management of binge eating disorder: current and emerging treatment options.Therapeutics and clinical risk management · 2012Article
- Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians.Therapeutic advances in chronic disease · 2011Article
- The effects of stiripentol on GABA(A) receptors.Epilepsia · 2011Review
- Update on treatment of partial onset epilepsy: role of eslicarbazepine.Neuropsychiatric disease and treatment · 2010Article
- Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.Neuropsychiatric disease and treatment · 2010Article
- Antiepileptic drug interactions - principles and clinical implications.Current neuropharmacology · 2010Article
- Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Lacosamide: in partial-onset seizures.Drugs · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is still a need for new antiepileptic drugs (AEDs) as the clinical efficacy, tolerability, toxicity or pharmacokinetic properties of existing AEDs may not be satisfactory. One new AED has recently been approved (rufinamide in 2007) and six others are in late-stage development (phase III and onwards) [brivaracetam, carisbamate, eslicarbazepine, lacosamide, retigabine and stiripentol]. The purpose of this review is to provide updated data on proposed mechanisms of action, efficacy and tolerability on these new AEDs, and to discuss the rationale for their development and possible advantages compared with existing treatment, based on recent publications and MEDLINE searches.Rufinamide, brivaracetam and stiripentol have been given the status of orphan drugs. Rufinamide was approved in Europe in 2007 for the use in Lennox-Gastaut syndrome. Brivaracetam has gained orphan status for development in progressive and symptomatic myoclonic seizures in Europe and the US, respectively. Stiripentol has gained orphan status in children with Dravet's syndrome and pharmaco-resistant epilepsy. All of these drugs demonstrate efficacy as adjunctive therapy in partial seizures. Three of the drugs are derivatives of existing AEDs: brivaracetam is a derivative of levetiracetam with improved affinity for the target molecule; carisbamate is a derivative of felbamate with improved tolerability; and eslicarbazepine is a derivative of carbamazepine with less interaction potential and no auto-induction. Lacosamide, retigabine, rufinamide and stiripentol are new compounds, unrelated to other AEDs.Further investigation and development of new broad-spectrum drugs is important for improved treatment of patients with epilepsy and other neurological and psychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.